Posts Tagged ‘NAMI’

Behind the Psychopharmaceutical Industrial Complex; Pharma-funded front groups masquerading as “patient advocates”

Tuesday, June 22nd, 2010

Scoop Independent News
By Evelyn Pringle
June 22, 2010

Non-Profit Advocacy Groups

As a main component of the Psychopharmaceutical Industrial Complex, the so-called “patient advocacy” organizations have become the leading force behind the American epidemic of mental illness over the past two decades.

Drug makers, and their foundations, funnel millions of dollars to these non-profits every year. In return, the leaders recruit their members as foot soldiers to carry out the latest marketing campaigns and to provide a fire-wall so that no money trail can be tracked back to the drug companies.

Gigantic Pyramid

The psychiatric front groups form a gigantic pyramid and once pharmaceutical money enters the system through a major organization, it gets channeled into a huge spider-web that weaves through many groups, making it nearly impossible to keep track of where it came from or where it all went. Often, when the grant reports of the drug companies list a large donation to one organization, the annual reports of the other groups will show smaller gifts from that same organization.

The “charity” groups are exempt from income tax and the “contributions” funneled through them are tax deductible. The money is used for disease mongering campaigns to both market disorders and pressure public health care programs and private insurers to pay for expensive treatments.

“Presenting themselves as patient advocacy groups is highly disingenuous not only to their membership, many of which may have a sincere desire to help a loved one or a family member with mental problems, but to legislators, the press and the American public — for they have consistently lobbied for legislation that benefits the mental health and pharmaceutical industries which fund them, and not patients they claim to represent,” according to Citizens Commission on Human Rights International, a mental health watchdog group.

In a June 2, 2010, commentary titled, “Psychiatric Fads and Overdiagnosis,” on the Psychology Today website, Dr Allen Frances points out that it “is too bad that there is no advocacy group for normality that could effectively push back against all the forces aligned to expand the reach of mental disorders.”

The leaders of the supposedly “non-profits” earn outrageously high salaries, along with excellent benefit packages, while many of the patients they claim to represent are encouraged to seek federal disability payments of under $700 a month, and apply for public housing, food stamps, and Medicaid, to make ends meet. The top officials will often move from a leadership role in one organization to a higher position in another.

The drug makers rely on the front groups to do their bidding any time profits are threatened. For instance, if the FDA is considering adding a black box warning about a deadly side effect to a drug’s label, which may result in a drop in sales, representatives of front groups will show up at the FDA advisory panel hearings to testify against adding the warning.

They will also lobby FDA panels whenever there is a chance to increase profits, such as enlarging the drug customer base. In June 2009, the Psychopharmacologic Drugs Advisory Committee was set to meet to evaluate AstraZeneca’s Seroquel, Pfizer’s Geodon and Eli Lilly’s Zyprexa for use with 13 to 17 year-olds diagnosed with schizophrenia, and 10 to 17 year-olds diagnosed with pediatric bipolar disorder.

On June 8, 2009, nine front groups issued a joint statement urging the panel to vote to approve all three drugs for kids. The groups signing the letter included the American Academy of Child and Adolescent Psychiatry, American Foundation for Suicide Prevention, American Psychiatric Association, Child and Adolescent Bipolar Foundation, Children and Adults with Attention-Deficit/Hyperactivity Disorder, Families for Depression Awareness, Mental Health America, National Alliance on Mental Illness, and the National Council for Community Behavioral Healthcare.

Read entire article:  http://www.scoop.co.nz/stories/HL1006/S00162.htm

Also see:  http://www.cchrint.org/psycho-pharmaceutical-front-groups/

« Return to news items


  • Share/Bookmark

The Troubling Link Between Big Pharma and the American Psychiatric Association

Tuesday, March 30th, 2010

The Faster Times
By Alison Bass
March 30, 2010

First the good news: The Physician Payment Sunshine Act is now law, signed by President Obama as part of the health care bill overhaul. Starting in 2012, drug and medical device companies must report all consulting, speaking and other payments to doctors and teaching hospitals in excess of $100 annually to the federal Department of Health and Human Services, which will post the payments on a public website. This is an important first step toward making transparent the pervasive financial ties between doctors who are studying or promoting specific drugs and medical devices and the companies that manufacture these products.

There is one significant loophole in the law: according to thefinal provisions, payments related to clinical trials or product development agreements for new products are allowed a publication delay of four years or until product approval, whichever comes first. So if a particular doctor is researching a drug that has not yet been approved for a specific condition, we will have to wait four years to find out whether he or she is on the drug company’s payroll. But at least the disclosure will eventually see the light of day, and patients who are prescribed the drug in question can seek a second opinion from a doctor who is not on the drug firm’s payroll and whose medical judgment can be trusted.

The Physician Payment Sunshine Act, however, only goes so far. While it covers doctors and teaching hospitals, it does not extend to all the advocacy groups and professional organizations that have substantial influence on over how particular illnesses are treated. For example, as I reported, the National Alliance for the Mentally Ill (NAMI), the most powerful advocacy group for people with mental illness, received millions of dollars in funding from drug companies for years — a payola that no doubt spurred this group’s embrace of potent psychoactive drugs over alternative methods of treating mental illness.

And now, in the current Psychiatric Times, two Massachusetts researchers tear the veil off efforts by the American Psychiatric Association (APA) to hide industry funding of its two philanthropic arms — the American Psychiatric Foundation (APF) and the American Psychiatric Institute for Research and Education (APIRE). As Lisa Cosgrove and Harold Burszstajn report: “While the APA recently announced it would phase out the visibly industry-supported educational programs, the organization has remained curiously silent about acknowledging and monitoring industry funding” of APF and APIRE.

Read entire article:  http://thefastertimes.com/healthinvestigations/2010/03/30/the-troubling-link-between-big-pharma-and-the-american-psychiatric-association/

« Return to news items


  • Share/Bookmark

Mandating Mental Health Coverage—a blank check for Psycho/Pharma to get everyone diagnosed mentally ill & drugged

Wednesday, February 3rd, 2010

JBS.org
By Beverly K. Eakman
February 2, 2010

We’ve all heard of “urban sprawl.” But there is another kind of “sprawl” Americans should find more worrisome: legislative sprawl.

Mental health parity is one such example. Government-mandated parity of mental and physical ailments for insurance coverage is a back-door route to nationalized health care. Special interests have been pushing government to implement parity for years and last Friday, January 29, the Obama Administration acquiesced. Health plans will henceforth be required to provide (not merely “offer”) mental-health benefits that contain no zingers, such as separate annual deductibles or lesser rates for psychiatrists and social workers.  Instead, according to Andrew Sperling of the National Alliance on Mental Illness (NAMI), health insurers will be obliged to give the same level of coverage for treatment of emotional angst “as they do for cancer, diabetes and heart disease.” Mental health has morphed into a cottage industry with scores of advocating organizations and lobbyists — NAMI, the American Psychiatric Association, Children and Adults with Attention-Deficit/Hyperactivity Disorders (CHADD), the National Education Association and, of course, pharmaceutical companies. Industry bigwigs have repeatedly insisted that mental-health issues are no different than physical illnesses. The problem is that one cannot verify a mental illness — not with an X-ray, a blood test, a urinalysis or by any other means. Unlike brain injuries, Alzheimer’s and other clear-cut brain impairments due to strokes, high fevers and birth defects, mental illness per se is purely subjective. Perhaps someday researchers will discover issues at the cellular level that definitively cause a certain subset of behaviors, or which exacerbate stress, but at the moment they cannot. So it is no wonder that the various medications and therapies directed at curing, or even alleviating, emotional distress have virtually no track record of success.

Read entire article:  http://www.jbs.org/jbs-news-feed/5917-legislative-sprawl-mandating-mental-health-coverage

« Return to news items


  • Share/Bookmark

Think They Don’t Electroshock People Anymore? Think Again–Even toddlers and pregnant women are being shocked

Sunday, January 24th, 2010

By Dr. John Breeding, author of The Wildest Colts Make the Best Horses

child close-upAsk the average person about the use of electroshock treatment in today’s society and 9 out of 10 will respond, “They still shock people?”

They do. It’s estimated that more than 100,000 Americans are electroshocked each year; half are 60 and older, and two-thirds are women. In Australia, it was recently revealed that psychiatrists had electroshocked 55 toddlers age four and younger. In the UK, three year olds have been brutalized with it. And one of the country’s leading mental health “patients’ rights” groups—the National Alliance of Mental Illness (NAMI)—recently endorsed the use of electroshock on pregnant women. One would wonder why a patients’ rights group would endorse such an obviously harmful procedure if not for the fact that the group has recently been exposed as a major front for the psycho/pharmaceutical industry.

The FDA reports pregnant women miscarrying following ECT, while studies show that in addition to the risk of death, the fetus can suffer malnutrition, dehydration and violent injury. Electroshocking children, pregnant women and the unborn is tantamount to torture and should not only be banned but those administering it prosecuted.

Given the factual truths of sending up to 360 volts of electricity searing through the brain – the obvious question is why the “treatment” has not gone by the wayside like its psychiatric sister treatments during the 1940s and 1950s, insulin coma shock and lobotomy.

Electroshock was indeed challenged, and its low point pretty much coincided with the release in 1975 of the Academy Award-winning film version of Ken Kesey’s One Flew Over the Cuckoo’s Nest and Jack Nicholson’s portrayal of the feisty Randle Patrick McMurphy. The horrible scene of his undergoing “unmodified” shock treatment, i.e., without anesthetic and muscle-paralyzing drugs, along with his reduction to a vegetative state was seared in the public’s mind. This, together with public exposure of the shameful state of psychiatric institutions, certainly gave electroshock treatment a bad name—so much so that the treatment was renamed Electroconvulsive Therapy (ECT). The bad publicity caused its use in public institutions to fall sharply, and its overall use was also considerably diminished. It would be naïve, however, to think that this curtailment was strictly due to increased public awareness about the brutalities of the procedure. The advent of neuroleptics (nerve-seizing drugs) was perhaps the major factor in this development. The indiscriminate use of these drugs replaced the indiscriminate use of ECT as the primary means of subduing and pacifying inmates who resisted incarceration and wouldn’t cooperate.

In the last two decades, however, electroshock has made a comeback.

Most electroshock is insurance-covered. ECT specialists on average have incomes twice that of other psychiatrists. The cost for inpatient ECT ranges from $50,000 to $75,000 per series (usually 8 to 12 individual sessions). Electroshock is a multibillion-dollar-a-year industry—yet its damaging effects are well known to those who endorse it.

Max Fink, a professor of psychiatry and the “Grandfather of American ECT” believed the “therapeutic” effect from ECT is produced by brain dysfunction and damage. “Effects on memory, common in ECT, come in two flavors,” wrote Fink in Psychiatric Times in 2006. “Delirium is common with each seizure and is well documented by immediate measurable changes in brain chemistry and physiology” and “the second complaint is of a persistent loss of personal memories…They do not recall the names of their children, family holidays, or personal events….Their complaints cast a public shadow on ECT practice.”

The Procedure

Electroshock is a psychiatric procedure that involves the production of a grand mal convulsion, similar to an epileptic seizure, by passing from 70 to upwards of 600 volts of electric current through the brain for one-half second to four seconds. Before application, ECT subjects are typically given anesthetic, tranquilizing and muscle-paralyzing drugs to reduce fear, pain, and the risk (from violent muscle spasms) of fractured bones (particularly of the spine, a common occurrence in the early history of ECT before the introduction, in the mid-1950s, of the muscle-paralyzing drug succinylcholine [Anectine]). The ECT-induced convulsion usually lasts from thirty to sixty seconds and may immediately produce disorienting, painful, and even life-threatening complications, such as apnea (temporary suspension of breathing) and cardiac arrest. The convulsion is followed by a period of unconsciousness of several minutes’ duration. Electroshock is usually administered in hospitals because they are equipped to handle emergency situations that often develop during or soon after an ECT session.

Brain Damage

The brain naturally operates in millivolts of electricity, and ECT administers on average between 150 and 400 volts of electricity to the brain, a force sufficient to induce a grand mal seizure, rupture the protective blood-brain barrier and incite glutamate toxicity (glutamate is a powerful neurotransmitter released by nerve cells in the brain and is responsible for sending signals between nerve cells. In glutamate toxicity there is too much glutamate that leads to over-excitation of the receiving nerve cell, which can cause cell damage and/or death). It is prima-facie, common sense obvious fact that ECT causes brain damage. After all, the rest of medicine, as well as the building trades, do their best to prevent people from being hurt or killed by electrical shock. People with epilepsy are given anticonvulsant drugs to prevent seizures because they are known to damage the brain. The Electroshock Quotationary, a collection of quotations, excerpts, and essays about the history and nature of electroshock, by shock survivor Leonard Roy Frank, includes the testimony of Peter Sterling, a University of Pennsylvania neuroscience professor, describing the nature of ECT-caused brain damage, dated May 31, 2001, to the New York Assembly Standing Committee on Mental Health at a public hearing on ECT.

Sterling affirms the obvious: that massive amounts of electricity directly into the brain cause profound damage.

Lack of Efficacy

Not only does electroshock directly violate the Hippocratic oath to do no harm, the practice has never been proven effective. There are no lasting beneficial effects of electroshock; sham-electroshock (anesthesia but no electroshock) has the same short-term outcomes as electroshock (Ross, 2006). Even leading shock researcher and advocate Harold Sackeim now provides a proof. In an article from 2001, he and his colleagues conclude, “Our study indicates that without active treatment, virtually all remitted patients relapse within 6 months of stopping ECT.” (Italics mine)

The FDA

The battle against electroshock has been ongoing since its advent. The two recent chronicles by electroshock survivor activist leaders, Leonard Roy Frank (The Electroshock Quotationary) and Linda Andre (Doctors of Deception), tell the story best. Just now, the fight has centered on the FDA review of the “efficacy and safety” of ECT machines.

Many activists, including myself, have submitted testimony urging the FDA NOT to reclassify these devices from Class III (high risk) to Class II (low risk). I have worked with scores of electroshock survivors, and I can tell you the damage is consistent and terrible. I can also tell you as a psychologist that there are methods so much gentler, safer and more effective to help people with depression.

A Repackaged Product

The reason for electroshock’s endurance and resurgence is best described by Linda Andre, shock survivor and leader of the Committee for Truth in Psychiatry, in her masterful new work, Doctors of Deception: What They Don’t Want You to Know About Shock Treatment—it is simply the triumph of public relations over science. A concerted PR campaign has allowed electroshock to continue despite clear scientific evidence of its dismal and tragic record on safety and efficacy.

The industry repackaged the product to keep it selling. They touted a “newer and safer ECT,” bragging about improved equipment and the introduction of anesthesia and muscle paralysants, which actually came on the market in the 1950s. While the muscle paralysants greatly reduced the risk of broken bones from unrestrained convulsions, there was no lessening of permanent damage to the brain caused by the electroshocks. The drugs made the procedure appear much more benign because they suppressed the body’s natural, violent reaction to a grand mal convulsion. However, as Doug Cameron (1994) and other researchers have shown, the new machines, because they are more powerful than ever are capable of releasing greater amounts of electricity into the brain thus causing more damage than the older devices.

With the newer technique modifications there is also an added risk. The drugs used to prevent bone complications raise the seizure threshold so that more electrical current is required to induce the convulsion, which in turn increases brain damage. Moreover, whereas ECT specialists formerly tried to induce seizures with minimal current, they commonly use suprathreshold amounts in the belief that they are more effective. Again, the more current, the more brain damage. Proponents, and the public, have missed the point that the supposed “effectiveness” of ECT is in direct ratio to the amount of brain damage it causes.

In addition to the propaganda effect and the financial incentives, there is a less well-considered reason for ECT’s popularity among psychiatrists. Although electroshock is often described as psychiatry’s “treatment of last resort,” it is actually psychiatry’s “treatment of next resort.” Next resort after psychiatric drugs, which are the main “treatment”—a treatment whose lack of effectiveness and lack of safety are well documented. Like ECT, these drugs can damage and disable the brain. Like ECT, they can cause a fully justified resentment that goes with the experience of having been betrayed by one’s supposed helpers.

Activist and electroshock survivor Leonard Roy Frank’s recent letter to the FDA in regards to their review of ECT devices is one of the best. I end this blog article with his conclusion:

As a destroyer of memories and thoughts, electroshock is a direct, violent assault on these hallmarks of American liberty: freedom of conscience, freedom of belief, freedom of thought, freedom of religion, freedom of speech, freedom from assault, and freedom from cruel and unusual punishment. Tens of thousands of people every year in the United States are deceived or coerced into undergoing electroshock. The FDA should do everything in its power to discourage the use of electroshock by:

  • keeping ECT’s Class III, high-risk rating;
  • insisting that electroshock psychiatrists, manufacturers of ECT devices, and executives and administrators in hospitals where ECT is administered, substantiate with scientific proof their claims that the procedure is “safe and effective”;
  • and calling upon the Congress and the Department of Justice to investigate the fraudulent and coercive use of this cruel and inhuman procedure.

Despite the evidence of grievous harm and failure to help, electroshock’s proponents rave on; as an example, an electroshock psychiatrist told Washington Post reporter Sandra Boodman in 1996, that, “ECT is one of God’s gifts to mankind. There is nothing like it, nothing equal to it in efficacy or safety in all of psychiatry.”

Given that ECT causes brain damage, memory loss, and other serious cognitive impairment, electroshock serves to cover up and impede any potential malpractice or personal injury litigation. It generally takes years for a shock survivor to recover enough to figure out what has happened to them, and most states have a statute of limitations (usually one or two years) on medical malpractice and personal injury suits. As a result, electroshock survivors are effectively prevented from pursuing litigation against those who harmed them, making electroshock psychiatrists almost malpractice-proof.


John Breeding, Ph.D. has been a counseling psychologist in Austin, Texas for 25 years.
He is an outspoken critic of electroshock treatment and has testified against its use before legislative bodies on numerous occasions. Dr. Breeding is also the director of Texans For Safe Education, a citizens group dedicated to challenging the ever-increasing role of psychiatric drugs in schools. He is the author of numerous articles and four books including:
The Wildest Colts Make the Best Horses and True Nature and Great Misunderstandings.

For more information on the damage caused by ECT, visit www.endofshock.com

References

Ayd Jr., F.T. (November-December 1963). “Guest editorial: Ugo Cerletti, M.D. (1877-1963),” Psychosomatics, Vol. 4, pp. A-6 – A-7.

Boodman, S.G. (September 24, 1996). “Shock therapy: It’s back,” Washington Post (Health Section), pp. 14-20.

Frank, Leonard Roy, The Electroshock Quotationary, June 2006, www.endofshock.com/102C_ECT.PDF.

Andre, Linda, Doctors of Deception, www.doctorsofdeception.com.

Kalinowsky, L.B. (1988). Quoted in R. Abrams, “Interview with Lothar Kalinowsky, M.D.,” Convulsive Therapy, Vol. 4.

Ross, C.A. (Spring 2006). “The sham ECT literature: Implications for consent to ECT,” Ethical Human Psychology and Psychiatry, Vol. 8.

Sackeim, H.A. et al. (March 14, 2001). “Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy,” Journal of the American Medical Association.

Sackeim, H.A. (2001). “Memory loss: From polarization to reconciliation,” Journal of ECT, vol. 17, no. 3, p. 229. Sackeim, H.A., Prudic, J. et al. (January 2007). “The cognitive effects of electroconvulsive therapy in community settings,” Neuropsychopharmacology, Vol. 32, pp. 244-254.

RETURN TO BLOGS PAGE


  • Share/Bookmark

NAMI – the ‘patients rights’ group which is really funded by & a major lobbying arm of Psycho/Pharma – is on the defensive

Tuesday, December 15th, 2009

Ed Silverman
Pharmalot
December 15, 2009

The National Alliance on Mental Illness is on the defensive. After reports that most donations made to the big advocacy group came from drug makers in recent years, NAMI agreed to disclose its funding sources. The disclosure, however, came after protracted criticism of NAMI for coordinating lobbying efforts with drug makers and pushing legislation that also benefits the pharma industry.

The embarassing episode prompted NAMI’s executive director, Michael Fitzpatrick, to acknowledge industry donations were excessive and that things would change. Meanwhile, board member Richard Lamb resigned over the issue, complaining little was changing, saying NAMI’s dependence on drugmakers made some actions impossible, such as warning against the use of some mental health drugs with life-threatening side effects.

Read entire article: http://www.pharmalot.com/2009/12/nami-runs-a-survey-on-pharma-funding/?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+Pharmalot+(Pharmalot)

« Return to news items


  • Share/Bookmark

Senator Grassley tells TeenScreen Executive Director (& former head of NAMI) to disclose all TeenScreen pharma funding

Sunday, December 13th, 2009

United States Senate
Committee on Finance
Washington, D.C. 20510-6200

December 7, 2009

Via Electronic Transmission

Laurie Flynn
Executive Director
TeenScreen National Center for Mental Health Checkups at Columbia University
1775 Broadway, Suite 610
New York, NY 10019

Dear Ms. Flynn:

The United States Senate Committee on Finance (Committee) has jurisdiction over the Medicare and Medicaid programs and, accordingly, a responsibility to the more than 100 million Americans who receive health care coverage under these programs. As Ranking Member of the Committee, I have a duty to protect the health of Medicare and Medicaid beneficiaries and safeguard taxpayer dollars authorized by Congress for these programs.

For the last three years, the Committee has been looking into various aspects of the pharmaceutical industry, including consulting arrangements, and industry funding for Continuing Medical Education (CME). My inquiry was spurred, in part by press accounts documenting the lack of transparency in the relationships between the pharmaceutical industry and nonprofit organizations. For instance, in April 2008, The Wall Street Journal reported that industry representatives, including ten major drug
companies, formed a coalition to promote looser restrictions on off-label marketing. The coalition asked the National Alliance on Mental Illness (NAMI) to speak in favor of this issue.

On October 6th of this year, I sent letters to all fifty state chapters of NAMI asking them to disclose income from pharmaceutical companies. In that letter, I explained that NAMI National receives almost two-thirds of its funding from the drug industry.  I learned recently that a few days after I sent those letters, one of the founders of NAMI and member of the NAMI National Board of Directors emailed his resignation,
stating that he was shocked at NAMI’s reliance on pharmaceutical industry funding. In particular he said: “This financial dependency presents a number of problems.”

Read entire letter: http://www.psychsearch.net/Letter_to_TeenScreen.pdf

« Return to news items


  • Share/Bookmark

How Vested Interests Created the Perfect Marketing/Lobbying Machine: Mental Health “Advocacy” Groups—Funded by Pharma

Thursday, December 10th, 2009

by CCHR International

An ongoing U.S. Senate investigation headed by Senator Charles Grassley has  sought disclosure of pharmaceutical funding paid to researchers, physicians,  medical schools and medical journals.  Some of the nation’s most prominent psychiatrists have now been exposed for extensive conflicts of interest amounting to millions in undisclosed pharmaceutical funding, including Dr. Charles Nemeroff, Dr. Joseph Biederman, Dr. Melissa DelBello, Dr. Timothy Wilens, Dr. Thomas Spencer, Dr. Alan Schatzberg, Dr. Martin Keller, Dr. A. John Rush, Dr. Karen Wagner, Dr. Jeffrey Bostic and Dr. Frederick Goodwin — many of which serve as advisory board members to mental illness “advocacy groups” which are now also the subject of the Senate investigation for their undisclosed pharmaceutical funding.

The majority of the public may or may not be familiar with these so-called mental health advocacy organizations, such as the National Alliance on Mental Illness (NAMI), Children and Adults with Attention Deficit Hyperactivity Disorder (CHADD) or the myriad of bipolar, depression or ADHD “support groups” that are inundating the internet.

But they need to be.

These are groups operating under the guise of advocates for the “mentally ill,” which in reality are heavily funded pharmaceutical front groups – lobbying and working on state and federal laws which effect the entire nation — from our elderly in nursing homes to our military, pregnant women, nursing mothers and school children. Presenting themselves as patient advocacy groups is highly disingenuous not only to their membership, many of which may have a sincere desire to help a loved one or a family member with mental problems, but to legislators, the press and the American public — for they have consistently lobbied for legislation that benefits the mental health and pharmaceutical industries which fund them, and not patients they claim to represent.

Certainly any organization claiming to be for the rights of patients diagnosed mentally ill would have as their primary goal, full informed consent in the field of mental health – including full and complete disclosure of all drug risks, the right to refuse treatment, the right to know that psychiatric diagnoses are not medical conditions (evident by the fact there is not one confirmatory medical/scientific test). Above all such groups would provide patients with an abundance of information on non-harmful, non- drug, medical solutions and options considering the dangerous and well documented risks of psychiatric drugs by international drug regulatory agencies.

These groups do not.

A patients rights group for the mentally ill would never endorse something as absurd and obviously dangerous as giving electroshock to pregnant women, nor condone schools being able to require children to take a psychiatric drug as a condition of attending school. Furthermore, they would never be opposed to the FDA actually doing its job and finally issuing long overdue warnings that antidepressants can cause children to commit suicide, or issue warnings that ADHD drugs have serious and even deadly side effects. Yet these are just some of the actions condoned and promoted by these so-called patients rights groups.

As another example take the federally proposed bill, The Mothers Act; a previous version of this bill called on using a method of “screening” pregnant women and new mothers called EPDS, a screening method documented to triple the number of women diagnosed with Postpartum depression, according to a study published in Obstetrics & Gynecology. The Scandinavian Journal of Public Health stated that EPDS screening was unethical and should not be used. None of the so called advocacy groups for the mentally ill had any objections to this bill whatsoever, or endorsing such an unethical screening tool. They supported it. The bill would have passed with no objections from them whatsoever, if not for the dedication of real advocacy groups with no vested interests (ties to Pharma) opposing language in this bill that would have led to women being falsely diagnosed and put on dangerous psychiatric drugs to “treat” them, unnecessarily placing new mothers and their infants at great risk.

To put it simply, these groups are not what they appear to be. Yet their influence over legislation, lobbying, drug regulation (or lack thereof), and public relations campaigns is substantial and effects the entire nation. For they claim to be the voice of the “mentally ill.” But are they? Or are they the result of a brilliant marketing/lobbying campaign designed to benefit the industry that funds them—the Psycho/Pharmaceutical industry.

To find out how it all started click here: http://www.cchrint.org/psycho-pharmaceutical-front-groups/

« Return to news items


  • Share/Bookmark

Grassley asks more mental health ‘patients rights’ groups (for ADHD, Bi-Polar, TeenScreen, etc.) to disclose Pharma $$

Tuesday, December 8th, 2009

For several years now, Senator Grassley has conducted extensive oversight and sought disclosure of financial ties with industry from research physicians, medical schools, medical journals, continuing medical education, and the patient advocacy community.   Now Senator Grassley has asked 33 medical groups for information about their financial backing they get from the medical device, insurance and pharmaceutical industries, including several psychiatric front groups such as Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD), Depression and Bipolar Support Alliance, Mental Health America, NARSAD, Screening for Mental Health Inc. and the National Center for Mental Checkups at Columbia University (TeenScreen).  Senator Grassley’s previous inquiry into the National Alliance on Mental Illness (NAMI) found that the majority of funding received was from the pharmaceutical industry; more than $28 million from pharmaceutical companies in the last four years.

In just the last two years, Grassley investigated and exposed extensive financial conflicts of interest of prominent psychiatrists with the pharmaceutical industry amounting to millions of dollars including Dr. Charles Nemeroff, Dr. Joseph Biederman, Dr. Melissa DelBello, Dr. Timothy Wilens, Dr. Thomas Spencer, Dr. Alan Schatzberg, Dr. Martin Keller, Dr. A. John Rush, Dr. Karen Wagner, Dr. Jeffrey Bostic and former head of the National Institute of Mental Health, Dr. Frederick Goodwin.  Additionally, Grassley investigated the American Psychiatric Association and the funding they received from the pharmaceutical industry.

For the latest inquiry from Senator Grassley read this article: http://www.iowapolitics.com/index.iml?Article=179090

« Return to news items


  • Share/Bookmark

Believe it or not, NAMI says ‘safest way to treat severe depression in a pregnant woman is probably electroconvulsive (ECT) therapy’

Wednesday, November 25th, 2009

Believe it or not, The National Alliance for the Mentally Ill (NAMI),a “patient’s rights group” for the mentally ill, is promoting Electroshock (ECT) for pregnant women as safe and effective. NAMI has recently been exposed for their extensive Pharma funding (3/4 of their donations; $23 million came from Pharma ) which may help explain their long standing promotion and fierce endorsement of psychiatric drugs which they are now attempting to downplay after being the subject of a Senate investigation. Not surprising then is the fact that NAMI also lists Cyberonics, an ECT machine manufacturer as one of NAMI’s Corporate Sponsor in 2008.

From NAMI’s website “The safest way to treat severe depression in a pregnant woman is probably electroconvulsive (ECT) therapy. Patients and families are sometimes frightened by the idea of “shock treatment,” but in fact ECT is safer than antidepressant medication for a depressed pregnant woman. It can be used during any state of pregnancy, but is less risky after the first trimester. The most common side effect of ECT is short term memory loss. Less frequent side effects usually respond to simple treatment. These may include: headaches, mild muscle soreness, nausea, adverse reactions to anesthetic or muscle relaxants, and heartbeat irregularities.

Read entire article: http://www.nami.org/Content/ContentGroups/Helpline1/Pregnancy_Pointers_for_Women_with_Psychiatric_History.htm

« Return to news items


  • Share/Bookmark

Pharma’s Drug Ads: From Million Dollar TV Ads to $1.7 Billion Internet Marketing Campaign

Monday, November 16th, 2009

November 16, 2009

On November 13th, 2009, Pharmaceutical companies flocked to a two-day FDA hearing into online drug advertising, which could influence their use of social media on the net. 1 Already, the explosive growth in online advertising has intensified public concerns: the pharmaceutical industry spent more than $1 billion on Internet ads last year and is projected to spend $1.7 billion on such marketing efforts in 2012, according to the Direct Marketing Association.2

Both Eli Lilly and Merck have received warning letters this year from the FDA accusing them of misleading online advertisements.3 But while the FDA scrambles to monitor online ads, who monitors the psychiatric-pharmaceutical industry’s use of front groups to indirectly market their products?

A Washington Post article of June 16, 2009 reported that an increasing number of pharmaceutical firms are turning to social media tools, such as Facebook, YouTube, Twitter and MySpace, to market their products.  It cites how a community site sponsored by drugmaker McNeil called “ADHD Allies”—aimed at adults with ADHD—was established and offered an online podcast on financial advice and an “ADHD self-assessment tool.”4

British psychiatrist Joanne Moncrieff explains how this ultimately increases drug sales because only a biomedical approach is promoted: “Drug companies…provide funds for pro drug patient and carer groups and address advertising or disease promotion campaigns to the general public…This influence has helped to create and reinforce a narrow biological approach to the explanation and treatment of mental disorders and has led to the exclusion of alternative” treatments.5

Such websites do not mention company’s product but rather market the “disease.” In advertising, it can be accomplished through a strategy known as “condition branding,” where “mental illness” can be pitched just like cars, beer or laundry detergent.  Witness the brand name “bipolar” and “social anxiety disorder” that drug companies marketed at a fever pitch.

John Read, PhD, Psychology Department, University of Auckland did an analysis of 54 random “advocacy” groups for Post Traumatic Stress Disorder (PTSD) through the Internet. The results, published in the Journal of Trauma & Dissociation this year, found 42% of the websites received drug company funding. The researchers found:

  • “Patients tend to trust these organizations to act in an unbiased manner” but as earlier researchers argued in some cases “patient organizations have become a mouthpiece for the pharmaceutical industry in influencing regulatory authorities.”
  • “Drug company influence within the area of mental health is prevalent and now extends to the Internet. This influence is not always transparent. This study suggests that drug company sponsorship of websites leads to a greater emphasis on pharmacology in the treatment of PTSD,” Dr. Read’s report concludes.6

ADHD Allies/ADHD Moms

In June 2008 Concerta was given an expanded indication by FDA and is now indicated for patients aged 6 to 65.7 In July 2008, McNeill Pediatrics—a subsidiary of Ortho-McNeill Pharmaceuticals—launched what they called an “unbranded group” called “ADHD Moms.” ADHD Moms markets the trademarked name “Mom-bassadors” to get mothers into the Facebook page. 8

  • McNeill spuriously claims “the group is not product-specific, nor are there any advertisements for the company’s ADHD drug Concerta (methylphenidate).” Well not directly, but providing material for the site is a Dr. Quinn, a paid consultant and speaker for McNeil Pediatrics. 9 April White, who also provides content is a paid spokesperson for McNeil Pediatrics.10
  • On April 22 2009, McNeill launched a second ADHD-focused Facebook page called “ADHD Allies,” this time targeting adults.  The “Allies” are board members of another front group Attention Deficit Disorder Association (ADDA), funded by McNeill.11
  • The pharmaceutical company has trademarked “ADHD Allies” and “ADHD Moms.”  ADHD Allies was responsible for a “2008 Harris Interactive survey of 1,000 adults with ADHD.” Not surprisingly, the survey found the condition significantly affects them. 12

Log onto The Bipolar Journey: Living With Bipolar Depression website and while it does show AstraZeneca on the home page, there’s no mention of its blockbuster antipsychotic drug Seroquel, approved by the FDA in 2006 for “bipolar.”  The site looks like a patient information site providing facts about the “disease” and misleadingly saying that it may be caused by a chemical imbalance—for which there is no evidence.

It refers people to the National Alliance for the Mentally Ill (NAMI) that has received $23 million recently from at least 18 drug companies. The site shows that of 17 cites for the exhibit’s showing in 2009, 12 are conferences or events put on by NAMI.

It also links to The Depression and Bipolar Support Alliance, a group that received close to $1 million in pharmaceutical company funding in 2007.

According to an August 27 2009 press announcement, AstraZeneca launched its interactive exhibit, endorsed by New York psychiatrist Janet Taylor. The press release does not mention that Dr. Taylor has financial ties to the company.13

In 2005, global sales for Seroquel reached $2.8 billion.  October 20, 2006, company announced Seroquel was FDA approved for bipolar.14 Within a year, sales reached $3 billion and then soared again in 2008 to $4.66 billion.15

By funding social media front groups that talk only about the “disorder,” drug companies can overcome fears of running afoul of FDA regulations that govern drug advertising and “are embracing social networks to help brand and position their companies in a positive light with consumers and practitioners.”  The top 10 drug companies using social media are: Pfizer, Johnson and Johnson, Novartis, Boehringer Ingelheim, AstraZeneca US, Bayer, GlaxoSmithKline, Sanofi-Aventis, Roche, and Merck.16

This post was written by CCHR International.
Coming next from CCHR Int: Psycho Pharma Front Groups

1 “FDA Addresses Drug Ads in Online Social Media,” Red Orbit, 13 Nov. 2009.

3 “FDA Addresses Drug Ads in Online Social Media,” Red Orbit, 13 Nov. 2009.

5 Joanne Moncrief, in a “Study of the Influence of the Pharmaceutical Industry on Academic and Practical Psychiatry,” http://www.critpsynet.freeuk.com/pharmaceuticalindustry.htm

6 http://www.isst-d.org/jtd/mansell_&_read_ptsd_drug_cos_&_internet%20.pdf; Journal of Trauma & Dissociation, 10:9–23, 2009

12 “Adults ‘Facing’ ADHD: ADHD Allies™ Offers Unique Online Community for Adults with ADHD on New Facebook® Page,” http://multivu.prnewswire.com/mnr/concerta/36533/

RETURN TO BLOGS PAGE


  • Share/Bookmark